A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Clinical trial NCT03051659 · COMPLETED
Trial details
- NCT number
- NCT03051659
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-22
- Primary completion
- 2018-10-11
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.